InsidersTradesSigma
Track the Compass Therapeutics, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Compass Therapeutics, Inc. has logged 61 insider filings. Market capitalisation: €372.8m. The latest transaction was reported on 30 April 2026 (Acquisition). Among the most active insiders: Schuetz Thomas J.. The full history is openly available.
61
Insider Decl.
n/a
Thresholds
€15m
34 ops.
Buy Volume
€10m
4 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Compass Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$8.50.
43Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 30 April 2026
Declarations61 total
15,000 shares@ US$1.890.0080% mcap32.5% of flowCommon StockSEC:0001171843-26-002894:0
Canonical exit: 28 Jul 2026 (T+90)
25,000 shares@ US$1.890.013% mcap37.1% of flowCommon StockSEC:0001171843-26-002893:0
Canonical exit: 28 Jul 2026 (T+90)
25,000 shares@ US$1.890.013% mcap37.1% of flowCommon StockSEC:0001171843-26-002840:0
15,000 shares@ US$1.890.0080% mcap32.5% of flowCommon StockSEC:0001171843-26-002834:0
36,687 shares@ US$6.524.7% of flowCommon StockSEC:0001171843-26-000722:0
46,777 shares@ US$5.355.0% of flowCommon StockSEC:0001171843-26-000205:0
125,000 shares@ US$5.1746.8% of flowCommon StockSEC:0001171843-26-000062:0
250,000 shares@ US$5.1725.7% of flowCommon StockSEC:0001171843-26-000060:0
62,500 shares@ US$5.1778.7% of flowCommon StockSEC:0001171843-26-000056:0
150,000 shares@ US$5.1785.8% of flowCommon StockSEC:0001171843-26-000051:0
44,025 shares@ US$4.836.6% of flowCommon StockSEC:0001171843-25-007400:0
10,000 shares@ US$2.110.4% of flowCommon StockSEC:0001171843-25-003462:0
Canonical exit: 25 Aug 2025 (T+90)
3,571,428 shares@ US$1.5929.9% of flowCommon StockSEC:0000947871-25-000384:0
3,571,428 shares@ US$1.5929.9% of flowCommon StockSEC:0000947871-25-000385:0
20,000 shares@ US$1.54100.0% of flowCommon StockSEC:0001171843-25-002086:0
Canonical exit: 6 Jul 2025 (T+90)
20,000 shares@ US$1.42100.0% of flowCommon StockSEC:0001171843-25-002084:0
Canonical exit: 6 Jul 2025 (T+90)
41,687 shares@ US$3.505.4% of flowCommon StockSEC:0001171843-25-000735:0
58,054 shares@ US$1.864.0% of flowCommon StockSEC:0001171843-25-000195:0
400,000 shares@ US$1.65100.0% of flowCommon StockSEC:0001171843-24-006859:0
44,782 shares@ US$1.452.3% of flowCommon StockSEC:0001171843-24-000714:0
49,198 shares@ US$1.452.0% of flowCommon StockSEC:0001171843-24-000715:0
637,500 shares@ US$1.9343.4% of flowCommon StockSEC:0001171843-24-000178:0
1,753,125 shares@ US$1.9392.7% of flowCommon StockSEC:0001171843-24-000179:0
64,415 shares@ US$1.502.7% of flowCommon StockSEC:0001171843-23-007223:0
44,025 shares@ US$1.502.4% of flowCommon StockSEC:0001171843-23-007222:0
25 of 61 declarations
关于 Compass Therapeutics, Inc.
Compass Therapeutics, Inc.（股票代码：CMPX）是一家临床阶段的生物制药公司，在美国纳斯达克上市，总部位于马萨诸塞州波士顿。该公司专注于肿瘤学，并正在构建一个专有的抗体平台，旨在干预血管生成、免疫系统和肿瘤微环境的交叉点。其科学前提是，通过同时靶向血管生成驱动通路和免疫肿瘤机制，可以提高抗肿瘤活性。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1738021/000117184325007005/cmpx20250930_10q.htm)） Compass 成立于 2014 年，后于 2020 年通过反向并购成为上市公司，从而获得了公共资本市场的资金支持，用于临床开发。自成立以来，管理层已将几乎所有资源投入到研发、知识产权、人员配备和一般公司支持上。该公司仍处于商业化前阶段：尚未产生产品收入，并继续依赖股权融资和其他资本来源来支持运营。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1738021/000117184325002575/ars_042525.pdf)） 其产品线以新型抗体资产为中心，包括 CD137 激动剂抗体 CTX-471、PD-1 x PD-L1 双特异性抗体 CTX-8371 和 PD-1 x VEGF-A 双特异性抗体 CTX-10726。这些项目旨在作为单一制剂或联合治疗方案，增强抗肿瘤免疫反应。从竞争角度来看，Compass 在一个由大型制药和生物技术集团主导的拥挤且资本密集型生物技术领域运营，因此差异化严重依赖于临床数据、生物标志物逻辑以及高效推进资产开发的能力。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1738021/000117184325007005/cmpx20250930_10q.htm)） 从地理上看，该公司主要位于美国，其运营足迹以波士顿为中心，并通过专业研究机构和合作者开展临床活动。最近的进展令人鼓舞，但仍处于早期阶段：2025 年，Compass 报告称，tovecimig 在胆道癌的随机 2/3 期 COMPANION-002 研究中达到了主要终点，而 CTX-8371 在其 1 期项目和扩展队列中显示出确定的部分缓解，并且已开放或计划开放。管理层还表示计划于 2026 年启动 CTX-471 的 2 期研究。总体而言，CMPX 为投资者提供了一个高风险、数据驱动的肿瘤学故事，具有重要的科学选择性，但持续的融资需求和监管不确定性仍然是投资案例的核心。（[investors.compasstherapeutics.com](https://investors.compasstherapeutics.com/news-releases/news-release-details/compass-therapeutics-reports-2025-second-quarter-financial?utm_source=openai)）
